secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0000950170-25-077865
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting
--------------------------------------------------------------------------------

- Elected Matthew W. Foehr (28.1M for, 16.2M withheld) and Charles A. Rowland, Jr. (33.0M for, 11.3M withheld) as Class I directors.
- Ratified CBIZ CPAs P.C. as independent auditor for FY2025: 75.2M for, 992K against, 473K abstentions.
- Advisory say-on-pay proposal approved: 29.3M for, 14.5M against, 506K abstentions, 32.4M broker non-votes.
- Meeting quorum of 76.7M shares (68.3% of 112.3M outstanding shares) represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025077865/0000950170-25-077865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025077865/vktx-20250520.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-077865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer